DEVELOPMENT OF INTRAVENOUS ADMINISTRATION OF L-LYSINE-ALPHA-OXIDASE FROM TRICHODERMA CF. AUREOVIRIDE RIFAI BKMF-4268 REGIME CONTROLLED BY SAFETY AND EFFICACY OF TREATMENT

V. S Pokrovsky; E. M Treshalina; E. V Lukasheva; L. A Sedakova

doi:10.17816/onco39944

Russian Journal of Oncology ›› 2013, Vol. 18 ›› Issue (2) : 10 -14. DOI: 10.17816/onco39944

Articles

research-article

DEVELOPMENT OF INTRAVENOUS ADMINISTRATION OF L-LYSINE-ALPHA-OXIDASE FROM TRICHODERMA CF. AUREOVIRIDE RIFAI BKMF-4268 REGIME CONTROLLED BY SAFETY AND EFFICACY OF TREATMENT

Author information +

History +

PDF

Abstract

Various doses and modes of intravenous L-lysine-alpha-oxidase application on tumor models in mice under the control of efficacy and tolerability have been studied. Optimal choice scheme provides introduction of the first relatively high starting dose and subsequent maintenance doses comprising А or % of the first ("discrete" mode). The efficiency and an acceptable tolerability has been shown during "discrete" 5-fold treatment course with intravenous cumulative doses of 450-550 U/kg. By treating L-lysine-alpha-oxidase in the "discrete" mode following tumor-bearing mice have been sensitive: breast adenocarcinoma Sa755, B16 melanoma, adenocarcinoma of the colon AKATOL, cervical cancer, cervical 5, epidermoid carcinoma and Lewis lung plasmacytoma CI-406 (TROmax = 57-92%).

Keywords

L-lysine-alpha-oxidase / antitumor activity / intravenous

Cite this article

Download citation ▾

V. S Pokrovsky, E. M Treshalina, E. V Lukasheva, L. A Sedakova. DEVELOPMENT OF INTRAVENOUS ADMINISTRATION OF L-LYSINE-ALPHA-OXIDASE FROM TRICHODERMA CF. AUREOVIRIDE RIFAI BKMF-4268 REGIME CONTROLLED BY SAFETY AND EFFICACY OF TREATMENT. Russian Journal of Oncology, 2013, 18(2): 10-14 DOI:10.17816/onco39944

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Березов Т.Т. Молекулярные и биохимические основы энзимотерапии опухолей. Биомедицинская химия. 2005; 51: 235-47.

[2]	Лукашева Е.В., Березов Т.Т. L-лизин-а-оксидаза: физикохимические и биологические свойства. Биохимия. 2002; 67 (10): 1394-402.

[3]	Покровский В.С., Лесная Н.А., Трещалина Е.М., Лукашева Е.В., Березов Т.Т. Перспективы разработки новых ферментных противоопухолевых препаратов. Вопросы онкологии. 2011; 57 (2): 155-64.

[4]	Kusakabe H., Kodama K., Kuninaka A., Yoshino H., Misono H., Soda K. A new antitumor enzyme, L-lysine alpha-oxidase from Trichoderma viride. Purification and enzymological properties. J. Biol. Chem. 1980; 255(3): 976-81.

[5]	Лукашева Е.В., Лукашев А.Н., Покровский В.С., Трещалина Е.М., Шумилина Е.Ю., Аринбасарова А.Ю. и др. Исследование основных фармакокинетических параметров L-лизин-α-оксидазы. Вопросы медицинской, биологической и фармацевтической химии. 2013; 1: 57-62.

[6]	Миронов А.Н., ред. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Медицина. 2005.

[7]	Kusakabe H., Kodama K., Machida H., Midorikawa Y., Kuninaka A., Misono H. et al. Occurrence of a novel enzyme, L-lysine oxidase with antitumor activity in culture extract of Trichoderma viride. Agricult. Biol. Chem. 1979; 43 (2): 337-43.